Tirzepatide
US$ 24.51
history of glp 1 drugs The expanding landscape GLP-1 medicines Mapping the effectiveness and risks
Description
Urva S, et al
However, substantial research is needed to expand their utility, optimize delivery methods, and improve patient outcomes
doi: 10.3389/fimmu.2022.772446 27 RichardsPParkerHEAdriaenssensAEHodgsonJMCorkSCTrappSet al
Similarly, 56.8% of patients receiving exenatide once-weekly were antibody-positive (11.8% with high titer) at 24-30 weeks, and this percentage was reduced to 45.4% (9.2% with high titer) at 52 weeks
Published in 1981, this peptide consisted of 69 amino acids and was initially called glicentin (Thim, Moody)
